International Clinical Trial: A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735637) titled 'A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6)' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: AstraZeneca

Condition: Newly Diagnosed Multiple Myeloma (NDMM)

Intervention: Biological: AZD0120 Drug: Cyclophosphamide Drug: Fludarabine Drug: Melphalan (part of ASCT)

Recruitment Status: Not recruiting

Phase: Phase 3

Date of Fir...